Hemispherx Biopharma Inc (HEB.A) Quote| Reuters.com
Edition:
United States

Hemispherx Biopharma Inc (HEB.A)

HEB.A on American Stock Exchange

0.12USD
12:17pm EDT
Change (% chg)

$0.00 (+0.25%)
Prev Close
$0.12
Open
$0.12
Day's High
$0.12
Day's Low
$0.11
Volume
10,943
Avg. Vol
69,801
52-wk High
$0.21
52-wk Low
$0.06

HEB.A

Chart for HEB.A

About

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development... (more)
No analyst recommendations are available for HEB.A.

Overall

Beta: 0.49
Market Cap(Mil.): $28.87
Shares Outstanding(Mil.): 248.66
Dividend: --
Yield (%): --

Financials

  HEB.A Industry Sector
P/E (TTM): -- 41.10 35.71
EPS (TTM): -0.06 -- --
ROI: -61.48 -6.56 14.23
ROE: -61.48 -5.98 15.43

BRIEF-Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation

* Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company

Jun 08 2016

BRIEF-Hemispherx Biopharma says obtained omnibus assignment of all IP rights of ex-CEO Carter

* Hemispherx Biopharma Inc says on June 2, obtained omnibus assignment of all intellectual property rights of former CEO William Carter

Jun 06 2016

BRIEF-Hemispherx Biopharma renews sales, marketing, distribution and supply agreement with GP Pharm

* Renews sales, marketing, distribution and supply agreement with GP Pharm

May 31 2016

BRIEF-Hemispherx Biopharma amends and restates agreement with myTomorrows

* Hemispherx amends and restates agreement with myTomorrows for the early access program for rintatolimod in Europe

May 23 2016

BRIEF-Hemispherx Biopharma qtrly loss per share $0.01

* Hemispherx biopharma announces financial results for the three months ended march 31, 2016

May 16 2016

BRIEF-Hemispherx biopharma enters into Alfa-n3 interferon clinical trial with Saudi Arabian's pharma co to fight MERS disease

* N3 interferon clinical trial, sales, marketing, distribution, and supply agreement with Saudi Arabia's premier pharma company in fight against the deadly MERS disease

Apr 04 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF80.15 +0.40
Pfizer Inc. (PFE.N) $35.08 +0.07
Merck & Co., Inc. (MRK.N) $57.45 +0.40
GlaxoSmithKline plc (GSK.L) 1,604.50p +45.00
AstraZeneca plc (AZN.L) 4,467.00p +86.50
Baxter International Inc (BAX.N) $45.00 +0.18
MediGene AG (MDG1k.DE) €6.66 +0.08

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.